PHBA Stock Chart & Stats
€45.60
€0.60(1.33%)
At close: 4:00 PM EDT
€45.60
€0.60(1.33%)
Day’s Range― - ―
52-Week Range€35.20 - €52.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€14.19B
Enterprise Value€14.53K
Total Cash (Recent Filing)€722.10M
Total Debt (Recent Filing)€1.71B
Price to Earnings (P/E)32.0
Beta0.81
Next Earnings
Nov 12, 2026EPS Estimate
0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.44
Shares Outstanding298,134,030
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)4.16
Price to Sales (P/S)3.01
P/FCF Ratio17.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.31
Revenue Forecast (FY)€4.09B
Bulls Say, Bears Say
Bulls Say
Hearing-aid Product Momentum And Share GainsStrong wholesale growth and share gains indicate effective product differentiation and sustained demand for new platforms. Recurring revenue from Virto R and continued launches can strengthen Sonova’s competitive position across professional channels.
High Profitability And Strong Cash ConversionHigh margins and reliable conversion of earnings into cash support ongoing investment in research, product launches, and retail expansion. This profitability also gives Sonova flexibility to fund shareholder returns and selective acquisitions without excessive financial strain.
Multi-channel Growth And International ExpansionThe combination of wholesale, retail, and APAC expansion diversifies growth beyond one channel or geography. Store openings, professional distribution, and rising Asian demand create multiple durable avenues for gaining hearing-care customers over the medium term.
Bears Say
Recent Revenue Decline And Margin CompressionDespite strong absolute profitability, the recent top-line contraction and lower net margin show that growth and earnings quality are not uniformly improving. Sustained pressure could reduce operating leverage and constrain the pace of reinvestment or returns.
Cochlear Implant Weakness And China ExposureThe cochlear implant business faces weaker volumes, competitive pressure, and China procurement changes. Dependence on regulatory approval and successful adoption of a new processor makes recovery timing uncertain and leaves a meaningful business exposed to execution risk.
One-off Costs And Foreign-exchange PressureLegal, product-liability, and impairment charges can reduce reported earnings and highlight risks from legacy products and systems. Ongoing currency translation pressure may also obscure underlying progress and make margins less predictable for shareholders.
Sonova Holding AG News
PHBA FAQ
What was Sonova Holding AG Unsponsored ADR’s price range in the past 12 months?
Sonova Holding AG Unsponsored ADR lowest stock price was €35.20 and its highest was €52.00 in the past 12 months.
What is Sonova Holding AG Unsponsored ADR’s market cap?
Sonova Holding AG Unsponsored ADR’s market cap is €14.19B.
When is Sonova Holding AG Unsponsored ADR’s upcoming earnings report date?
Sonova Holding AG Unsponsored ADR’s upcoming earnings report date is Nov 12, 2026 which is in 64 days.
How were Sonova Holding AG Unsponsored ADR’s earnings last quarter?
Sonova Holding AG Unsponsored ADR released its earnings results on May 18, 2026. The company reported €1.233 earnings per share for the quarter, beating the consensus estimate of €1.232 by <€0.001.
Is Sonova Holding AG Unsponsored ADR overvalued?
According to Wall Street analysts Sonova Holding AG Unsponsored ADR’s price is currently Overvalued.
Does Sonova Holding AG Unsponsored ADR pay dividends?
Sonova Holding AG Unsponsored ADR does not currently pay dividends.
What is Sonova Holding AG Unsponsored ADR’s EPS estimate?
Sonova Holding AG Unsponsored ADR’s EPS estimate is 0.93.
How many shares outstanding does Sonova Holding AG Unsponsored ADR have?
Sonova Holding AG Unsponsored ADR has 298,134,030 shares outstanding.
What happened to Sonova Holding AG Unsponsored ADR’s price movement after its last earnings report?
Sonova Holding AG Unsponsored ADR reported an EPS of €1.233 in its last earnings report, beating expectations of €1.232. Following the earnings report the stock price went up 6.487%.
Which hedge fund is a major shareholder of Sonova Holding AG Unsponsored ADR?
Currently, no hedge funds are holding shares in DE:PHBA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sonova Holding AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.23%
12-Months-Change
Fundamentals
Return on Equity
2.03%
Trailing 12-Months
Asset Growth
4.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sonova Holding AG Unsponsored ADR
Sonova Holding AG is a prominent developer, manufacturer, and global distributor of hearing health solutions for all age groups. The company's operations are divided into two core areas: Hearing Instruments and Cochlear Implants. Its product range includes sophisticated wireless communication devices, innovative rechargeable hearing aids, and a comprehensive selection of consumer audio electronics such as wireless headsets, hearables designed for speech enhancement, high-fidelity headphones, microphones, and wireless transmission systems. Furthermore, Sonova offers extensive audiological care services. Key brands under its umbrella include Phonak, Unitron, and Hansaton for hearing instruments; Advanced Bionics for cochlear implants; and Sennheiser for consumer audio. Its audiological care services are delivered through a vast network of approximately 3,600 retail locations and clinics, known by various regional names including AudioNova, Audium, and Connect Hearing. Sonova distributes its products through independent partners and provides services via its direct network. The company maintains a significant international presence, operating in the United States, Europe, the Middle East, Africa, and the Asia Pacific region. Established in Stäfa, Switzerland, in 1947, the firm was formerly known as Phonak Holding AG before adopting its current name, Sonova Holding AG, in August 2007.
PHBA Company Deck
PHBA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong product-led sales momentum (notably in wholesale and select APAC markets), meaningful operating leverage, high cash conversion and disciplined capital allocation. Key short-term challenges are concentrated in the Cochlear Implants business (notably China) and several non‑core one-off charges plus FX headwinds. Management provided a confident but execution‑sensitive midterm roadmap (innovation, multi-channel expansion, operational savings) and reiterated growth and margin guidance for FY26/27.View all DE:PHBA earnings summariesTechnical Analysis
Abbott Laboratories
―
Medtronic
―
LivaNova
―
Inspire Medical Systems
―
Envoy Medical
―